10-Q: INmune Bio Reports First Quarter 2024 Results, Cites Going Concern Uncertainty Amidst Increased R&D Spending

INmune Bio's first quarter 2024 results show a net loss of $11.0 million and increased research and development expenses, raising concerns about the company's ability to continue as a going concern.

Summary

• INmune Bio reported a net loss of $11.0 million for the three months ended March 31, 2024, compared to a net loss of $6.5 million for the same period in 2023.
• The company's research and development expenses increased significantly to $8.7 million in Q1 2024 from $4.1 million in Q1 2023, primarily due to increased spending on the Alzheimer's clinical program.
• Cash and cash equivalents decreased to $26.0 million as of March 31, 2024, from $35.8 million at the end of 2023.
• The company's management has expressed substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
• INmune Bio is exploring various financing strategies, including equity sales, debt financing, and strategic alliances, to secure additional funding.
• The company is advancing its DN-TNF platform, particularly XPro for Alzheimer's and treatment-resistant depression, and its INKmune platform for cancer therapies.
• A Phase II trial for XPro in early Alzheimer's is underway, with enrollment expected to be completed by mid-year 2024.
• The company has terminated further enrollment in the MDS/AML trial for INKmune, but is continuing a Phase I/II trial in metastatic castrate-resistant prostate cancer.

Sentiment

Score: 3

Explanation: The document highlights significant financial losses, a going concern warning, and increased R&D spending, which are major negatives. While there are some positive developments in clinical trials, the overall sentiment is negative due to the financial instability and uncertainty.

Positives

• The company is actively progressing its Phase II trial for XPro in early Alzheimer's disease, with enrollment expected to be completed by mid-year 2024.
• The Phase I trial for XPro in Alzheimer's showed promising results, including decreases in neurodegeneration biomarkers.
• The company has initiated a Phase I/II trial of INKmune in metastatic castrate-resistant prostate cancer, with initial data expected in September 2024.
• INmune Bio has a diverse pipeline with two therapeutic platforms targeting different disease areas.
• The company has secured a $2.9 million grant from the National Institute of Mental Health for a trial of XPro in treatment-resistant depression.

Negatives

• The company's net loss has significantly increased to $11.0 million in Q1 2024.
• The company's cash reserves have decreased to $26.0 million.
• Management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has terminated further enrollment in the MDS/AML trial for INKmune.
• The company is reliant on external funding to continue operations.

Risks

• The company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern.
• The company is dependent on securing additional financing through various means, which may not be available on favorable terms.
• The company's product candidates are still in development and may not receive regulatory approval or be commercially viable.
• The company faces competition from other pharmaceutical and biotechnology companies.
• The company relies on a small number of vendors for manufacturing supplies, which could be disrupted.
• Fluctuations in foreign exchange rates could adversely affect the company's financial results.

Future Outlook

The company expects to continue to incur significant losses for the foreseeable future as it continues its research and development efforts and seeks regulatory approvals for its product candidates. The company is also exploring various financing strategies to secure additional funding.

Management Comments

• Management is currently evaluating different strategies to obtain the required funding of future operations.
• Management has concluded that its plans do not alleviate substantial doubt about the company's ability to continue as a going concern.

Industry Context

The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory hurdles. INmune Bio's focus on innate immune system modulation aligns with a growing interest in immunotherapies for various diseases. The company's challenges in securing funding and achieving profitability are common among early-stage biotech companies.

Comparison to Industry Standards

• INmune Bio's increased R&D spending is typical for a clinical-stage biotech company advancing multiple programs.
• The company's cash burn rate is concerning, especially given the going concern warning, and is higher than some peers at a similar stage.
• The company's reliance on external funding is common in the biotech industry, but the uncertainty around securing additional capital is a significant risk.
• The company's focus on novel mechanisms of action, such as DN-TNF and NK cell priming, differentiates it from companies using more traditional approaches.
• The company's Phase II trial in Alzheimer's is comparable to other companies in the space, but the use of an enrichment strategy and the EMACC endpoint are notable.
• The company's decision to terminate the MDS/AML trial is not uncommon in early-stage clinical development, as companies often need to prioritize resources.

Related Party Transactions

• The company recorded $23,000 and $112,000 of prepaid expenses related party for payments made to UCL in advance of services to be provided as of March 31, 2024 and December 31, 2023, respectively.
• The company owed AmplifyBio $31,000 and $10,000 as of March 31, 2024 and December 31, 2023, respectively, in connection with medical research performed on behalf of the company.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and the potential for dilution from future capital raises.
• Employees may be concerned about job security given the company's going concern warning.
• Customers and partners may be hesitant to engage with the company due to the financial uncertainty.
• Creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to complete enrollment in the Phase II Alzheimer's trial by mid-year 2024.
• Top-line cognition data from the Phase II Alzheimer's trial is expected six months after the last patient is enrolled.
• The company plans an end-of-phase II meeting with the FDA to finalize plans for the pivotal Phase III trial.
• The company plans to apply for Fast Track status in 2024 and expects to be eligible for Break Through status after completion of the Phase II trial in 2025.
• The company expects to report data from each cohort of the Phase I/II trial of INKmune in metastatic castrate-resistant prostate cancer as it becomes available.
• The company expects the Phase I portion of the INKmune prostate cancer trial to be completely enrolled in September 2024.
• The company estimates the INKmune prostate cancer trial will be completely enrolled in 1H25 with top-line data available 6 months later.

Key Dates

Keywords

INmune Bio, Biotechnology, Clinical Stage, Immunology, DN-TNF, XPro, INKmune, Alzheimer's Disease, Cancer, Neuroinflammation, Research and Development, Clinical Trials, Going Concern, Financial Results